Overview

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Status:
Active, not recruiting

Trial end date:
2023-09-16

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma). Drugs used in chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Phase:

Phase 2

Details

Lead Sponsor:

Emory University

Collaborator:

Celgene

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Gemcitabine
Paclitaxel